MedTrace Logo

Comparison of Treatment Modalities in Poor Responders Undergoing IVF

NCT02158689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-01-08

No results posted yet for this study

Summary

The accurate identification and efficient management of poor responders remains one of the most enigmatic challenges in assisted reproductive technology (ART). The investigators study will compare the letrozole/antagonist protocol to the hMG/antagonist protocol in women who poor responders.

Conditions

  • Poor Responders

Interventions

DRUG

Letrozole

DRUG

human menopausal gonadotropin (hMG)

Sponsors & Collaborators

  • Ercan Bastu

    lead OTHER

Principal Investigators

  • Harika Yumru, M.D. · Istanbul University School of Medicine

  • Hasan F Buyru, M.D. Prof. · Istanbul University School of Medicine

  • Ercan Bastu, M.D. · Istanbul University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02158689 on ClinicalTrials.gov